The effect of hypoalbuminemia for cefuroxime dosing in critically ill patients with low levels of albumin or renal failure is likely to have significant consequences on the drug's pharmacodynamics (PD) and pharmacokinetics (PK). This evidence concerns the gene ALB and acute kidney injury.